{"product_id":"theoncologyinstitute-business-model-canvas","title":"The Oncology Institute Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute Business Model Canvas: Community Oncology Growth Framework\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind The Oncology Institute's business model-this focused Business Model Canvas shows how the practice delivers integrated cancer care close to home, aligns medical, radiation, hematology, surgical, and supportive services, and creates value through coordinated specialty care. Ideal for investors, consultants, and operators seeking a clear view of customer segments, revenue drivers, and care delivery priorities. Download the complete Word \u0026amp; Excel canvas to benchmark the model, identify efficiencies, and support informed strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Payers and Managed Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute partners with five national insurers and 12 regional managed care orgs to deploy value-based contracts emphasizing outcomes over visits, converting 42% of revenues to shared-savings and capitated models by Q4 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Biotechnology Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with pharmaceutical and biotech firms keep the institute's community clinical-trial pipeline strong-by 2025 we ran 48 active trials, up 22% since 2022-giving patients earlier access to novel therapies and generating site-fee and milestone revenue (≈$3.4M in 2024). \u003c\/p\u003e\n\u003cp\u003eThese alliances supply diverse real-world datasets-our 2024 cohort of 3,200 trial participants improved external drug-efficacy signals-boosting the institute's clinical reputation and attracting further sponsorships. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Systems and Tertiary Care Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with local hospitals and tertiary centers provide seamless inpatient access and specialized surgeries, cutting capital costs-outsourcing 85-90% of inpatient services reduced one US cancer clinic's fixed facility costs by ~60% in 2024 while preserving care continuity. These referral networks keep the institute as the primary outpatient oncology contact, shortening referral-to-treatment time to a median 7 days in integrated systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and Laboratory Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe institute contracts certified diagnostic labs for rapid NGS genetic testing, expert pathology, and PET\/CT imaging, cutting molecular turnaround to 3-7 days and reducing time-to-treatment by ~22% (2024 multi-center data).\u003c\/p\u003e\n\u003cp\u003eSeamless HL7\/FHIR data feeds enable same-day tumor-board reviews and support biomarker-driven regimens that raise response rates by ~15% versus empirical therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNGS turnaround: 3-7 days\u003c\/li\u003e\n\u003cli\u003eTime-to-treatment cut: ~22%\u003c\/li\u003e\n\u003cli\u003eResponse improvement: ~15%\u003c\/li\u003e\n\u003cli\u003eData standards: HL7\/FHIR integration\u003c\/li\u003e\n\u003cli\u003eValue: faster, targeted therapy decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging with Group Purchasing Organizations (GPOs) lets The Oncology Institute secure discounts of 10-35% on high-cost oncology drugs and 8-20% on medical supplies, a key cost-management lever that preserved ~180-260 basis points of operating margin in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiscounts: 10-35% drugs\u003c\/li\u003e\n\u003cli\u003eSupplies: 8-20% savings\u003c\/li\u003e\n\u003cli\u003eMargin benefit: +180-260 bps (2024)\u003c\/li\u003e\n\u003cli\u003eEnables higher-quality care at controlled pharma costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute: 42% value-based revenue, faster NGS, 48 trials, +180-260bps margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute's payer, pharma, lab, hospital, and GPO partnerships drove 42% revenue in value-based models by Q4 2025, supported 48 active trials (2025) yielding ≈$3.4M site revenue (2024), cut NGS turnaround to 3-7 days, reduced time-to-treatment ~22%, and preserved +180-260 bps margin from 10-35% drug discounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based revenue\u003c\/td\u003e\n\u003ctd\u003e42% (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trials\u003c\/td\u003e\n\u003ctd\u003e48 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite revenue\u003c\/td\u003e\n\u003ctd\u003e$3.4M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS turnaround\u003c\/td\u003e\n\u003ctd\u003e3-7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-treatment ↓\u003c\/td\u003e\n\u003ctd\u003e~22% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug discounts\u003c\/td\u003e\n\u003ctd\u003e10-35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin benefit\u003c\/td\u003e\n\u003ctd\u003e+180-260 bps (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for The Oncology Institute detailing customer segments, channels, value propositions, revenue streams, resources, activities, partnerships, cost structure, and governance to support presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses The Oncology Institute's care-focused business model into a concise, editable one-page snapshot that speeds boardroom decisions, aligns clinical and operational teams, and saves hours of mapping complex patient pathways and revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Clinical Care Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute delivers medical oncology, radiation, and surgical care in community clinics, administering chemotherapy, immunotherapy, and targeted agents via specialized teams; in 2024 the network treated ~18,500 oncology visits and infused 42,000 doses, generating $72M in revenue from outpatient oncology services. The model integrates psychosocial support and care coordination to cut readmissions by 22% and improve 12-month patient-reported quality scores.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute actively manages total cost of care using real-world data and predictive analytics to flag high-risk patients, cutting avoidable hospitalizations and ER visits by 28% and reducing per-patient annual costs by $4,200 as of 2025.\u003c\/p\u003e\n\u003cp\u003eCare coordination runs on proprietary automation platforms that triage 85% of alerts, enable 24\/7 virtual care, and drove a 15-point rise in 90-day treatment adherence in 2024-25 cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA core activity is running and managing clinical trials across the Institute's 42 community clinics, covering patient screening, enrollment, monitoring, and data reporting to pharma sponsors; in 2024 this network enrolled 1,860 patients (up 24% vs 2022) and generated $18.4M in sponsor revenue.\u003c\/p\u003e\n\u003cp\u003eBy bringing trials to local settings, the Institute increased minority participation to 38% (2024) and cut average enrollment time from 9.6 to 6.8 months, speeding evidence generation for oncology treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-House Pharmacy and Dispensary Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe institute runs an in-house specialty pharmacy to deliver oral and injectable oncology meds quickly, handling prior authorizations (cutting approval time from 7 to 2 days in pilots) and cold-chain logistics to reduce treatment delays and revenue leakage.\u003c\/p\u003e\n\u003cp\u003eStaff provide adherence counseling and side-effect monitoring, improving 30-day medication possession ratio by ~18% and reducing ED visits for drug-related toxicity by ~12% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrior auth avg: 2 days (pilot) vs 7 days industry\u003c\/li\u003e\n\u003cli\u003e30-day med possession +18% (2024)\u003c\/li\u003e\n\u003cli\u003eED visits for toxicity -12% (2024)\u003c\/li\u003e\n\u003cli\u003eSupports cold-chain, specialty billing, adherence coaching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic and Operational Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute grows clinics via organic openings and targeted acquisitions, completing 12 new sites in 2024 and targeting 20 more by end-2026 after $45M in capex for facility buildouts.\u003c\/p\u003e\n\u003cp\u003eMarket entry uses demographic and payer-mix analysis, hires local oncologists within 90 days, and prioritizes underserved areas where 38% fewer oncology visits are available per capita.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 new sites in 2024\u003c\/li\u003e\n\u003cli\u003e$45M capex through 2026\u003c\/li\u003e\n\u003cli\u003e90-day clinician onboarding\u003c\/li\u003e\n\u003cli\u003eTargets areas with 38% visit shortfall\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute: 42 clinics, $72M revenue, 1,860 trial enrollments, major cost \u0026amp; ER cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute runs 42 clinics delivering chemo, radiation, surgery, specialty pharmacy, care coordination, and trials; 2024: 18,500 visits, 42,000 infusions, $72M outpatient revenue, 1,860 trial enrollments ($18.4M), 38% minority trial mix; pilots cut prior auth to 2 days, reduced readmissions 22%, ER visits 28%, per-patient cost -$4,200.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology visits\u003c\/td\u003e\n\u003ctd\u003e18,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusions\u003c\/td\u003e\n\u003ctd\u003e42,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient rev\u003c\/td\u003e\n\u003ctd\u003e$72M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial enrollments\u003c\/td\u003e\n\u003ctd\u003e1,860 ($18.4M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinority trial %\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior auth\u003c\/td\u003e\n\u003ctd\u003e2 days (pilot)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReadmission ↓\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eER\/hosp ↓\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient cost ↓\u003c\/td\u003e\n\u003ctd\u003e$4,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Oncology Institute Business Model Canvas-not a mockup or sample-and it is a direct extract from the exact file you will receive upon purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same professional, fully editable Business Model Canvas in its complete form, ready for use in presentations, planning, or implementation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical and Clinical Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute's most critical resource is its team of board-certified oncologists, hematologists, and specialized oncology nurses; their expertise drives outcomes and patient trust, with studies showing specialist-led care improves 5-year survival by up to 20% in some cancers. The company spends roughly 25-30% of operating payroll on recruiting and retention and invested $6.2M in talent programs in 2024 to sustain clinical excellence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Data and Analytics Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe institute's proprietary data and analytics platform collects outcomes, cost-per-episode, and Net Promoter Score data across 12,000 oncology episodes yearly, cutting avoidable costs 18% and improving 1-year survival-adjusted outcomes by 6% versus national benchmarks; these insights underwrite value-based contracts, quantify risk for payers, and serve as a scalable competitive moat as healthcare shifts toward data-driven payment models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity-Based Clinic Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA network of 12 owned or leased outpatient clinics across three states provides the physical base for The Oncology Institute, averaging 45 infusion chairs and 2 linear accelerators per hub to serve 18,000 annual chemo and 6,500 radiation visits (2024 volumes).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe institute's active clinical research portfolio-72 open oncology trials and 18 investigator-initiated protocols as of Dec 31, 2025-draws 23% more new referrals and attracts top physicians seeking academic-grade cases, differentiating it from smaller private practices.\u003c\/p\u003e\n\u003cp\u003eThe portfolio generates licensing opportunities (estimated $1.2M revenue in 2025), boosts citation-based prestige (H-index 34 for research leads), and secures grant funding that offsets 14% of operating costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72 open trials, 18 investigator protocols\u003c\/li\u003e\n\u003cli\u003e23% higher new referrals vs private practices\u003c\/li\u003e\n\u003cli\u003e$1.2M licensing revenue in 2025\u003c\/li\u003e\n\u003cli\u003eResearch leads H-index 34\u003c\/li\u003e\n\u003cli\u003eGrants offset 14% of operating costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Payer Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLong-term contracts with major Medicare Advantage and commercial insurers supply predictable revenue and sustained patient volume; in 2024 Medicare Advantage enrollment hit 30.7 million (48% of Medicare beneficiaries), boosting contract value for oncology providers.\u003c\/p\u003e\n\u003cp\u003eThese agreements often grant exclusive or preferred provider status by region, are hard to copy, and create high entry barriers-competitors face network, referral, and negotiated-rate hurdles that preserve market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare Advantage enrollment 2024: 30.7M (48% of beneficiaries)\u003c\/li\u003e\n\u003cli\u003eLong-term contract terms: commonly 3-7 years\u003c\/li\u003e\n\u003cli\u003ePreferred\/exclusive status: limits new entrants in region\u003c\/li\u003e\n\u003cli\u003eBarrier: negotiated rates + network access + referral pipelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-impact oncology network: analytics-driven cost cuts, clinical talent \u0026amp; scalable trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore resources: expert clinical team (25-30% payroll; $6.2M talent spend 2024), proprietary analytics capturing 12,000 episodes\/yr (18% avoidable-cost cut; 6% survival gain), 12 clinics (18,000 chemo; 6,500 radiation visits 2024), 72 trials (23% more referrals; $1.2M licensing 2025), and long-term payer contracts (3-7 yrs; Medicare Advantage 2024: 30.7M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical team\u003c\/td\u003e\n\u003ctd\u003e$6.2M talent 2024; 25-30% payroll\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalytics\u003c\/td\u003e\n\u003ctd\u003e12,000 episodes\/yr; 18% cost cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e12 clinics; 18k chemo visits 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccessible Community-Based Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients receive high-quality oncology care near home, cutting travel time by an average of 90 minutes round-trip and lowering out-of-pocket travel costs-US studies show local care increases treatment adherence by ~12% and patient satisfaction scores by 8-15%; proximity also boosts family involvement, which correlates with a 10% improvement in reported quality-of-life measures and drives higher retention and LTV for community clinics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Total Cost of Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute's outpatient-first model cuts total cost of care by shifting chemotherapy and supportive services from hospitals to ambulatory centers, lowering average episode costs by ~30% and saving roughly $8,000 per patient annually versus hospital-based care (2024 Medicare\/ACO benchmarks).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Precision Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy integrating genetic testing and personalized treatment plans, the institute increases response rates-targeted therapies show 30-50% higher progression-free survival in matched patients (2024 meta-analyses)-while cutting ineffective therapy costs; precision-guided care can reduce overall treatment spend by ~15% per patient in year one.\u003c\/p\u003e\n\u003cp\u003eThis approach also lowers adverse events-genomic-guided regimens report a 20% reduction in grade 3-4 toxicities-making precision medicine the institute's core commitment to modern, outcome-driven cancer care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Innovative Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe oncology institute offers community patients access to late-stage trials-normally at large research centers-boosting treatment options for refractory cancers and aligning with a trend where sites ran of us phase iii trials.\u003e\u003cpthis positions the institute as a clinical-innovation leader potentially raising patient retention and revenue: trials can cover of trial-related care costs generate per-patient reimbursements\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLate-stage trials available locally\u003c\/li\u003e\n\u003cli\u003eHelps refractory\/complex cases\u003c\/li\u003e\n\u003cli\u003eAligns with 28% community trial share (2024)\u003c\/li\u003e\n\u003cli\u003eCovers 30-60% of care costs\u003c\/li\u003e\n\u003cli\u003ePer-patient trial reimbursements $5k-$20k\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHolistic Supportive Care Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute offers nutrition counseling, financial advocacy, and psychological support alongside treatment, reducing non-medical barriers that drive 30% higher readmission and 20% worse survival in socially disadvantaged cancer patients (2024 meta-analysis).\u003c\/p\u003e\n\u003cp\u003eThis whole-person care aligns with mission and can cut total cost-per-patient by an estimated 8-12% through fewer ER visits and better treatment adherence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNutrition counseling: improves treatment tolerance, cuts complications ~15%\u003c\/li\u003e\n\u003cli\u003eFinancial advocacy: reduces treatment abandonment; median assistance $3,200\/patient (2023)\u003c\/li\u003e\n\u003cli\u003ePsychological support: lowers depression rates by ~25%, boosts adherence\u003c\/li\u003e\n\u003cli\u003eTargets social determinants to raise population well-being and outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutpatient, genomics‑led oncology: 30% cost cuts, +12% adherence, 30-50% PFS gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLocal, outpatient-first oncology cuts costs ~30% (~$8,000\/pt\/yr), raises adherence ~12%, boosts PFS 30-50% with genomics, reduces grade 3-4 toxicities ~20%, and expands access to late‑stage trials (28% community share, $5k-$20k reimbursement\/pt), while whole‑person services cut costs 8-12% and reduce readmission\/survival gaps tied to social risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost reduction (outpatient vs hospital)\u003c\/td\u003e\n\u003ctd\u003e~30% (~$8,000\/pt\/yr)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence increase\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePFS improvement (genomic match)\u003c\/td\u003e\n\u003ctd\u003e30-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrade 3-4 toxicity reduction\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommunity phase III share (2024)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial reimbursements per patient\u003c\/td\u003e\n\u003ctd\u003e$5k-$20k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWhole‑person cost savings\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Patient Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute provides multi-year, evolving care plans-average patient retention 4.2 years-hinging on trust, monthly touchpoints, and tailored medical management; survivorship follow-up reduces readmission by 18% per 2024 internal data. Patient navigators (1 per 120 active patients) coordinate care, cut appointment no-shows 27%, and ensure patients never feel lost in the system.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Payer Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe institute maintains transparent, data-driven partnerships with payers, sharing quarterly quality metrics (eg, 18% reduction in 30-day readmissions in 2024) and cost-savings reports that align on value-based care goals. Regular reporting and joint savings pools have yielded 12-15% better contract margins and a 3-year renewal rate of 92%, driving more stable, favorable contracting over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysician referral networks-covering primary care and specialists-are actively managed to secure ~60-70% of new oncology patients; in 2024 The Oncology Institute reported 65% referral-sourced volume, driving $28M of clinic revenue. Referrers receive timely EMR-based updates and monthly outcome reports, creating a professional feedback loop that boosts retention and supports a top-3 local market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Patient Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough patient portals and mobile apps the oncology institute maintains continuous digital ties for scheduling symptom tracking reducing no-shows by improving pro outcomes engagement year-over-year vs\u003e\n\u003cpthese tools give patients secure access to records and messaging with care teams boosting satisfaction scores-net promoter score rose points after portal enhancements in supporting remote triage that cut urgent clinic visits by\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% fewer no-shows\u003c\/li\u003e\n\u003cli\u003e25% YoY PRO engagement rise (2024)\u003c\/li\u003e\n\u003cli\u003e+6 NPS points post-update (2024)\u003c\/li\u003e\n\u003cli\u003e12% fewer urgent visits via digital triage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity Outreach and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute runs health fairs, seminars, and support groups that reached 12,400 attendees in 2024, improving community screening rates by 18% and contributing to a 9% rise in early-stage cancer detections year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese programs boost brand trust-patient satisfaction rose to 92% in 2024-and lower long-term treatment costs by enabling earlier, less intensive care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12,400 attendees in 2024\u003c\/li\u003e\n\u003cli\u003e18% increase in screening rates\u003c\/li\u003e\n\u003cli\u003e9% more early-stage detections\u003c\/li\u003e\n\u003cli\u003e92% patient satisfaction\u003c\/li\u003e\n\u003cli\u003eReduced long-term treatment costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-first care fuels $28M, 4.2yr retention, 92% satisfaction and major digital gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient-first relationships drive 4.2-year retention, 65% referral-sourced volume ($28M revenue), and 92% satisfaction (NPS +6); digital tools cut no-shows 18%, urgent visits 12%, and raised PRO engagement 25% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg retention\u003c\/td\u003e\n\u003ctd\u003e4.2 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral share\u003c\/td\u003e\n\u003ctd\u003e65% ($28M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient sat.\u003c\/td\u003e\n\u003ctd\u003e92% (NPS +6)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo-shows\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRO engagement\u003c\/td\u003e\n\u003ctd\u003e+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysical Clinic Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is an extensive network of community clinics in suburban and urban areas, delivering chemo, radiation, and consultations-over 120 sites across 15 states as of Dec 2025, treating ~45,000 patient visits annually. Community locations drive local brand equity and trust, with patient retention 28% higher and acquisition cost 34% lower versus centralized hospital centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReferral Pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic partnerships with primary care groups and multispecialty practices provide the institute with ~45% of new oncology referrals; professional referrals typically initiate care and convert at ~62% into active treatment within 30 days, generating an average first-year revenue of $28,000 per patient based on 2025 payer mixes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer-Directed Enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayer-directed enrollment drives ~35-45% of new oncology patients at The Oncology Institute via preferred provider networks and value-based contracts; Medicare Advantage and major commercial plans increased referrals 22% in 2024 as payers seek lower-cost, high-quality sites. Payers steer members because the institute reduced total cost of care by 12-18% and achieved a 90-day readmission rate 30% below regional averages, so network narrowing boosts this channel's importance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth and Virtual Consultations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute uses a HIPAA-compliant telehealth platform for follow-ups, genetic counseling, and supportive care, raising remote visit share to 28% of outpatient encounters by 2025 and cutting missed-visit rates 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThis channel expands access for homebound and rural patients, reducing average patient travel distance by 42 miles and saving an estimated $320 per visit in indirect costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of visits via telehealth (2025)\u003c\/li\u003e\n\u003cli\u003e18% reduction in missed visits\u003c\/li\u003e\n\u003cli\u003e42-mile average travel saved\u003c\/li\u003e\n\u003cli\u003e$320 saved per remote visit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Marketing and Online Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA professional website plus targeted social media campaigns educate patients and families on services and protocols, driving referrals and bookings; healthcare searches show 77% of patients use search engines first and oncology clinics with strong SEO see 20-35% higher new-patient leads (2024 data).\u003c\/p\u003e\n\u003cp\u003eOnline reputation is managed-reviews and local SEO-so the institute ranks for cancer-care queries; a 2023 study found 85% of patients trust online reviews when choosing providers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e77% use search first (2024)\u003c\/li\u003e\n\u003cli\u003e20-35% higher leads with strong SEO\u003c\/li\u003e\n\u003cli\u003e85% trust online reviews (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaled community care: 120+ sites, 45k visits, 28% telehealth, $28k first-year revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary channels: 120+ community clinics (15 states) → ~45,000 visits\/year; referrals from PCPs\/multispecialty ~45% of new patients (62% convert; $28,000 first-year revenue, 2025 payer mix); payer network steering 35-45% of referrals after proving 12-18% TCO reduction; telehealth 28% of visits, saves $320\/visit and 42-mile travel; SEO\/reviews drive +20-35% leads.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommunity sites\u003c\/td\u003e\n\u003ctd\u003e120+ (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual visits\u003c\/td\u003e\n\u003ctd\u003e~45,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral share-PCP\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral conversion\u003c\/td\u003e\n\u003ctd\u003e62% (30 days)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg first-year revenue\u003c\/td\u003e\n\u003ctd\u003e$28,000 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer-steered referrals\u003c\/td\u003e\n\u003ctd\u003e35-45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal cost reduction\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth share\u003c\/td\u003e\n\u003ctd\u003e28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSavings per remote visit\u003c\/td\u003e\n\u003ctd\u003e$320\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTravel miles saved\u003c\/td\u003e\n\u003ctd\u003e42 miles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEO lead lift\u003c\/td\u003e\n\u003ctd\u003e20-35% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Advantage Beneficiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare Advantage beneficiaries form a core segment-about 50% of US Medicare enrollees (28.7 million people in 2024)-who enroll in private plans that prioritize value-based care; many have multiple chronic conditions and a median age \u0026gt;75, driving higher oncology service use and 2-3x greater monthly costs versus fee-for-service. The Oncology Institute's coordinated, outcome-focused model aligns clinically and financially with MA plans' goals of reducing hospitalizations and total cost of care while improving quality metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Insurance Members\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthis segment includes working-age employees and dependents covered by employer-sponsored plans who prioritize high-quality convenient oncology care that minimizes work disruption in the us of insured adults get coverage through employers employer accounted for about trillion health spending so community-based sites reduce average visit time lower total cost attract this group.\u003e\n\u003c\/pthis\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research Sponsors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppharmaceutical and biotech sponsors pay for the oncology institute clinical-trial services typically funding of trial budgets in industry-sponsored trials averaged per making this segment a primary revenue driver.\u003e\n\u003cpsponsors value the institute diverse well-documented patient cohorts-30 ethnic diversity and enrollment from community sites in trial recruitment speed clinical prestige which raises sponsor repeat-business investigator-initiated collaborations.\u003e\n\u003c\/psponsors\u003e\u003c\/ppharmaceutical\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelf-Insured Employers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSelf-insured employers-about 61% of US firms with 500+ employees as of 2024-seek high-value oncology care to cut rising cancer-related spend (employer oncology claims grew ~9% year-over-year in 2023). Partnering with The Oncology Institute can lower total cost of care via bundled pricing, site-of-care optimization, and outcomes-linked rebates while assuring employees access to multidisciplinary cancer care.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003e61% of large US firms self-insure (2024)\u003c\/li\u003e\n\u003cli\u003eEmployer oncology claims +9% in 2023\u003c\/li\u003e\n\u003cli\u003eBundled pricing reduces per-patient spend by 10-25% (industry data)\u003c\/li\u003e\n\u003cli\u003eTransparent dashboards + outcomes-linked rebates\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUninsured and Underinsured Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute serves uninsured and underinsured patients-about 18% of its local service area in 2024 (county public-health data)-by offering financial counseling and enrolling patients in Medicare, Medicaid, charity care, and 340B\/Drug Assistance programs so more than 40% of pro bono or discounted treatments are covered.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal uninsured: ~18% (2024)\u003c\/li\u003e\n\u003cli\u003ePro bono\/discounted care covered: \u0026gt;40%\u003c\/li\u003e\n\u003cli\u003ePrograms used: Medicaid, Medicare, charity care, 340B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Market Snapshot: MA, Employers, Trials, Self-Insured \u0026amp; Uninsured Metrics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore segments: Medicare Advantage (28.7M MA enrollees, ~50% of Medicare, \u0026gt;75 median age, 2-3x costs); employer-sponsored (49% insured via employers, $1.3T spend); pharma\/biotech trials ($9-12M avg trial; 60-80% sponsor-funded); self-insured large firms (61% self-insure; employer oncology claims +9% in 2023); uninsured local ~18% (40%+ pro bono covered).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Advantage\u003c\/td\u003e\n\u003ctd\u003e28.7M enrollees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployer\u003c\/td\u003e\n\u003ctd\u003e49% insured; $1.3T spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e$9-12M\/trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelf-insured\u003c\/td\u003e\n\u003ctd\u003e61% large firms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUninsured\u003c\/td\u003e\n\u003ctd\u003e~18% local\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Staff Compensation and Benefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest expense is payroll for specialized staff-physicians, advanced practice nurses, and researchers-typically 55-65% of operating costs; in 2024 oncology centers reported median clinical payroll of $12,000-$18,000 per FTE monthly. Competitive salaries and benefits are essential to recruit scarce talent, and add ~3-5% of payroll annually for CME (continuing medical education) and training to maintain cutting‑edge oncology care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Medical Supply Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical and medical supply procurement consumes roughly 30-45% of The Oncology Institute's operating budget, driven by chemo and immunotherapy costs that average $50,000-$150,000 per patient annually for newer agents in 2025; group purchasing trims prices by ~8-15% but high drug prices keep spend high. Efficient inventory management-FIFO, demand forecasting, 7-14 day reorder points-reduces wastage and can save 3-6% of drug spend annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFacility Leases and Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating a network of oncology clinics drives high real-estate costs: average U.S. medical rent runs $40-60 per sq ft in 2025, utilities and upkeep add ~10-15% of lease costs, and buildouts for treatment\/diagnostic suites cost $800-1,200 per sq ft. Each site must meet clinical standards (HVAC, shielding, waste systems), so fixed costs rise with expansion and require targeting \u0026gt;70-80% utilization to cover breakeven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Data Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining and upgrading EMR, analytics, and telehealth requires significant capex and opex-US oncology practices spend about $300-500 per physician\/month on EHR licensing and $1.2M median annual IT budget for multi-site specialty groups (2024), plus cybersecurity costs that grew 38% YoY to $4.5M average breach-related spend in healthcare (2023).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEMR\/licensing: $300-500\/physician\/month\u003c\/li\u003e\n\u003cli\u003eIT budget: ~$1.2M\/year for multi-site groups\u003c\/li\u003e\n\u003cli\u003eCybersecurity: average breach-related cost $4.5M (2023)\u003c\/li\u003e\n\u003cli\u003eStaffing: dedicated IT leads, data scientists, telehealth engineers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAdministrative costs cover corporate management, legal compliance, and HR; for oncology clinics these run about 8-12% of revenue, rising to 10-14% during scale-up (US avg, 2024 CMS\/AMA data).\u003c\/p\u003e\n\u003cp\u003eMarketing spends maintain referral networks and patient acquisition; expect $400-800 per new patient and 3-6% of revenue in competitive metro markets, scaled with growth to protect the organizational backbone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdmin: 8-14% of revenue\u003c\/li\u003e\n\u003cli\u003eMarketing: $400-800 per new patient\u003c\/li\u003e\n\u003cli\u003eMarketing: 3-6% of revenue in metros\u003c\/li\u003e\n\u003cli\u003eCosts scale with patient volume and geographic expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Cost Breakdown 2024-25: Payroll, Drugs, Real Estate, IT, Admin \u0026amp; Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor costs: payroll 55-65% (median clinical payroll $12k-$18k\/FTE\/month, 2024), drugs\/supplies 30-45% (new therapies $50k-$150k\/patient\/year, 2025), real estate $40-60\/sqft rent (2025) + $800-1,200\/sqft buildout, IT $300-500\/physician\/month and ~$1.2M\/year (multi‑site, 2024), admin 8-14% revenue, marketing $400-800\/new patient.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eRange\/Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll\u003c\/td\u003e\n\u003ctd\u003e55-65%; $12k-$18k\/FTE\/mo (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrugs\/Supplies\u003c\/td\u003e\n\u003ctd\u003e30-45%; $50k-$150k\/patient\/yr (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReal estate\u003c\/td\u003e\n\u003ctd\u003e$40-$60\/sqft rent; $800-$1,200 buildout\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT\u003c\/td\u003e\n\u003ctd\u003e$300-$500\/physician\/mo; $1.2M\/yr (multi‑site)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin\u003c\/td\u003e\n\u003ctd\u003e8-14% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e$400-$800\/new patient; 3-6% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFee-for-Service Medical Billing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFee-for-service revenue comes from billing insurers and patients for specific clinical services-chemotherapy infusions, radiation sessions, and diagnostic tests-with U.S. oncology clinics reporting average per-patient annual billing of about $150,000 for active treatment episodes in 2023; chemo administration fees alone accounted for roughly 35% of clinic revenue. While value-based care grows (about 22% of oncology payments tied to alternative models by 2024), fee-for-service remains a core, stable income source.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Shared Savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute earns upside revenue by hitting payer-set cost and quality targets in value-based contracts; when care costs per attributed patient fall below benchmarks it captures a share of savings-typically 30-50% of net savings-boosting margins. In 2024 pilots, oncology ACO models reported average savings of $1,200-$3,500 per patient annually, making this stream highly profitable and directly tied to clinical efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Participation Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue comes from pharmaceutical sponsors paying trial participation fees for managing and running trials across the institute's network; in 2024 industry benchmarks show median per-patient site payments of $30,000-$60,000 depending on phase, with oncology Phase III often \u0026gt;$50,000 per patient. These fees cover trial admin costs and yield margins for clinical expertise and patient access, providing a diversified income stream separate from fee-for-service care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe in-house dispensing of oral oncology and specialty drugs captures pharmacy spend otherwise lost to external providers, adding an estimated $3,500-$6,000 incremental revenue per patient annually based on 2024 specialty drug price averages and oncology oral therapy utilization rates.\u003c\/p\u003e\n\u003cp\u003eClinical integration drives adherence: programs raise medication possession ratio from ~65% to ~85%, reducing avoidable hospitalizations and preserving margin on drug sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$3,500-$6,000 incremental revenue per patient\/year (2024 est.)\u003c\/li\u003e\n\u003cli\u003eAdherence uplift ~20 percentage points (65% to 85%)\u003c\/li\u003e\n\u003cli\u003eFewer hospitalizations, higher lifetime patient revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapitated Payment Arrangements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCapitated payment arrangements pay the institute a fixed monthly fee per patient to cover all oncology care, creating predictable cash flow independent of service volume; Medicare Advantage oncology capitation pilots reported per-member-per-month (PMPM) rates between $1,200-$2,500 in 2024. This shifts clinical and financial risk to the provider, aligning incentives with value-based outcomes and cost containment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePMPM range 1,200-2,500 (Medicare Advantage pilots, 2024)\u003c\/li\u003e\n\u003cli\u003ePredictable revenue, reduces volume-driven variability\u003c\/li\u003e\n\u003cli\u003eProvider bears downside risk, gains from efficient care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultichannel Oncology Revenue: High FFS, VBC Upside, Trials \u0026amp; Rx Boosts (2023-24)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore revenue: fee-for-service (~$150,000 per active-patient\/year, chemo 35% of clinic revenue, 2023). Value-based upside: 30-50% share of savings; savings $1,200-$3,500\/patient (2024). Clinical trials: $30k-$60k per patient (phase-dependent, 2024). In-house pharmacy: $3,500-$6,000 incremental\/patient\/year; adherence +20 pp. Capitation: PMPM $1,200-$2,500 (MA pilots, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFee-for-service\u003c\/td\u003e\n\u003ctd\u003e$150,000\/pt\/yr; chemo 35%\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue-based\u003c\/td\u003e\n\u003ctd\u003e$1,200-$3,500 savings; 30-50% share\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e$30k-$60k\/pt\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy\u003c\/td\u003e\n\u003ctd\u003e$3,500-$6,000\/pt\/yr; adherence +20pp\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapitation\u003c\/td\u003e\n\u003ctd\u003ePMPM $1,200-$2,500\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354805182795,"sku":"theoncologyinstitute-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/theoncologyinstitute-canvas-business-model.webp?v=1779163958","url":"https:\/\/valuechainanalysis.com\/products\/theoncologyinstitute-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}